查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2003093

毒理学和药物筛检市场：按测试类型、产品类型、检体类型、药物类别、应用和最终用户划分－2026-2032年全球市场预测

Toxicology Drug Screening Market by Test Type, Product Type, Sample Type, Drug Class, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，毒理学药物筛检市场价值将达到 342.3 亿美元，到 2026 年将成长至 383 亿美元，到 2032 年将达到 861.5 亿美元，复合年增长率为 14.09%。

主要市场统计数据
基准年 2025 342.3亿美元
预计年份：2026年 383亿美元
预测年份：2032年 861.5亿美元
复合年增长率 (%) 14.09%

本执行概述概述了技术创新、监管压力和临床需求如何重塑毒理学药物筛检的策略和投资决策。

由于技术、法规和临床需求等多种因素的相互作用，毒理学中的药物筛检正处于转折点。分析仪器和分子诊断技术的进步扩大了可检测分析物的范围，并提高了灵敏度。同时，临床途径和法医学要求的演变也要求更快、更准确地获得结果。此外，实验室也面临越来越大的压力，需要提高处理能力、缩短结果时间，并确保符合不同司法管辖区的法规要求。

技术进步、验证要求以及分散式检查模型的整合如何重新定义药物筛检中的检查室操作和服务交付？

毒理学药物筛检领域正经历一场变革，其驱动力包括高解析度分析技术的整合、分子检测方法的普及以及对照护现场便利性的日益重视。层析法-质谱联用技术正从小众的确认工具发展成为可靠检测流程的基础，在复杂的药物基质和多重用药的情况下展现出更高的特异性。同时，免疫检测和侧向层析技术也不断发展，提供日益强大的筛检能力，与确认平台形成互补。

评估 2025 年关税变化对毒理学检测的采购、供应链韧性和服务交付的营运影响。

2025年推出的关税和贸易政策对毒理学检查室的采购、设备维护和耗材供应链产生了累积影响。进口设备和零件关税的提高可能会增加层析法系统、质谱仪和PCR设备的购置成本，迫使检查室重新考虑其采购计划，并优先考虑模组化升级而非整体平台更换。除了资本设备外，试剂、检测试剂盒和专用耗材的关税也会导致单位成本波动，进而影响检测项目的组成以及内部和外包确认检测服务的经济效益。

将测试方式、产品系列、检体基质、药物标靶、应用和最终用户趋势连结起来的多层次细分观点，以建立可操作的检查室策略。

详细的细分观点阐明了技术、临床和商业性优先事项在检测类型、产品系列、检体基质、药物标靶、应用和最终用户方面的交汇点。检测类型包括层析法和质谱平台，这些平台又细分为高可靠性确证气相层析层析法联用和液相层析法串联式质谱质谱联用，以及免疫检测筛检筛检和分子诊断，涵盖从下一代定序到基于PCR的检测方法。快速检测方案是上述检测的补充，并支援分散式筛检点的运作。

区域趋势和监管差异影响全球毒性测试市场的技术采用、供应链策略和服务交付模式。

区域趋势影响着技术采纳、监管合规和服务交付模式，并成为策略规划和供应商合作的关键要素。在美洲，医疗保健系统和法医学网路倾向于快速采用高解析度层析法和质谱技术，这得益于成熟的报销管道支援集中式检查室模式、大批量临床检测和确证性检测。监管要求强调经验证的检验调查方法和储存管理通讯协定，这些是刑事鑑定和职场检测的基础；同时，分散式医疗保健的趋势也推动了对快速现场筛检检测的需求成长。

竞争优势源自于毒理学测试中的整合仪器、检验的检测组合、服务伙伴关係以及供应链透明度。

药物筛检领域的竞争格局呈现出全球仪器製造商、专业检测方法开发公司以及提供确证检测和咨询服务的服务供应商并存的局面。领先的仪器供应商利用整合平台，将强大的层析法系统和高灵敏度质谱仪相结合，并配备用于数据收集、解读和检查室资讯管理的软体生态系统。这些供应商凭藉强大的处理能力、完善的支援网路和方法库脱颖而出，从而缩短复杂检测项目的检验週期。

为领导者提供的实用策略措施，以增强毒理学服务的韧性，使测试管道多样化，并优化采购和人力资源能力。

产业领导者应采取平衡策略，强调韧性、敏捷性和临床有效性。首先，应优先考虑在筛检和确证检测模式方面实现产品组合多元化，以应对供应链中断，并使检查室能够选择满足其临床和法医学需求的检测方法。同时投资于使用免疫检测的快速筛检和使用层析法-质谱联用技术的确证检测能力，将确保在关键案例中进行正确的分类，并维护结果的完整性。

为了提供实际的见解，我们采用了严谨的多方面研究途径，结合了专家访谈、监管审查、供应链映射和技术性能评估。

本分析所依据的研究采用了多模态方法，以确保其稳健性和对所有检查室环境的适用性。主要资料收集包括对实验室经理、采购经理和服务供应商进行结构化访谈，以了解实际营运、采购限制和验证实务。除这些定性见解外，还对监管指南、认证标准和技术验证文献进行了系统性回顾，以支持关于测试方法选择、报告和合规性的讨论。

策略整合强调技术整合、供应链韧性和人才培养，以确保可靠且可扩展的毒理学服务。

总之，毒理学药物筛检正朝着更一体化和技术主导的方向发展，这需要对仪器和检测方法的选择、供应链管理以及人力资源能力进行策略性协调。能够成功应对这项变革的检查室和服务供应商，能够恰当地平衡对可靠确认平台的投资与快速分子水平筛检工具的实际应用，以满足多样化的临床和法医学需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：毒理学和药物筛检市场：按测试类型划分

  • 层析法和质谱
    • 气相层析法联用
    • 液相层析法-串联式质谱质谱法
  • 免疫检测
  • 分子诊断
    • 下一代定序
    • 基于PCR的检测
  • 快速检测

第九章：毒理学和药物筛检市场：按产品类型划分

  • 层析法系统
  • 验证服务
  • 咨询服务
  • 酵素免疫分析法（ELISA）试剂盒
  • 侧向流动免疫检测试剂盒
  • 质谱仪
  • PCR装置
  • 筛检服务

第十章：毒理学和药物筛检市场：按检体类型划分

  • 血
    • 电浆
    • 全血
  • 头髮
  • 口腔液
  • 唾液
  • 尿

第十一章：毒理学药物筛检市场：依药物类别划分

  • 安非他命
  • 苯二氮平类药物
  • 大麻
  • 古柯碱
  • 阿片类药物

第十二章：毒理学和药物筛检市场：按应用领域划分

  • 临床诊断
  • 刑事鑑定
  • 疼痛管理
  • 体育反兴奋剂
  • 职场检查

第十三章：毒理学和药物筛检市场：按最终用户划分

  • 政府和军事实验室
  • 家庭测试
  • 医院和诊所
  • 私人考试机构
  • 研究机构

第十四章：毒理学和药物筛检市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：毒理学和药物筛检市场：按组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：毒理学和药物筛检市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国毒理学和药物筛检市场

第十八章：中国毒理学和药物筛检市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Alere Inc.
  • ARK Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Mindray Bio-Medical Electronics Co., Ltd.
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
Product Code: MRR-AD517FAA7D9A

The Toxicology Drug Screening Market was valued at USD 34.23 billion in 2025 and is projected to grow to USD 38.30 billion in 2026, with a CAGR of 14.09%, reaching USD 86.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.23 billion
Estimated Year [2026] USD 38.30 billion
Forecast Year [2032] USD 86.15 billion
CAGR (%) 14.09%

An executive overview that frames technological innovation, regulatory pressures, and clinical demand reshaping toxicology drug screening strategy and investment choices

The toxicology drug screening landscape stands at an inflection point driven by converging forces in technology, regulation, and clinical demand. Advances in analytical instrumentation and molecular diagnostics are expanding the scope of detectable analytes and improving sensitivity, while evolving clinical pathways and forensic requirements are demanding faster, more accurate results. At the same time, laboratories face intensified pressure to enhance throughput, reduce time-to-result, and maintain compliance across diverse jurisdictions.

This executive summary synthesizes key developments shaping test adoption and provider strategies. It speaks to clinical laboratory directors, procurement teams, forensic leaders, and manufacturers who must balance capital investments in chromatography and mass spectrometry platforms with scalable screening solutions such as immunoassays and rapid tests. The introduction frames the discussion by articulating how methodological choice, sample handling protocols, and downstream confirmatory workflows combine to determine operational performance and stakeholder confidence.

Through this lens, readers will find a clear orientation to recent innovations, regulatory inflections, and competitive dynamics that influence decision-making. The goal is to provide a concise yet comprehensive entry point that prepares leaders to interpret deeper segmentation analysis and regional intelligence supplied in subsequent sections.

How converging technological advances, validation requirements, and decentralized testing models are redefining laboratory operations and service delivery in toxicology screening

The landscape of toxicology drug screening is undergoing transformative shifts driven by the integration of high-resolution analytical techniques, the mainstreaming of molecular assays, and a renewed emphasis on point-of-care accessibility. Chromatography coupled with mass spectrometry has transitioned from a niche confirmation tool to a cornerstone of high-confidence testing workflows, yielding greater specificity for complex drug matrices and polypharmacy cases. Simultaneously, immunoassays and lateral flow technologies continue to evolve, offering increasingly robust screening capability that complements confirmatory platforms.

Next-generation sequencing and PCR-based modalities are extending toxicology beyond traditional metabolites to include genetic and pathogen interactions that influence drug metabolism and interpretation. This molecular overlay supports personalized approaches to pain management and forensic toxicology, while raising the bar for laboratory informatics and result interpretation. Rapid testing modalities are also becoming more clinically acceptable as sensitivity and specificity improve, enabling decentralized testing in workplace, emergency, and community settings.

Operationally, these technological shifts drive changes in capital allocation, workforce skill requirements, and quality assurance protocols. Laboratories must invest in staff training on mass spectrometric data interpretation and molecular assay validation. Meanwhile, cross-disciplinary collaboration between clinical chemists, molecular scientists, and IT specialists becomes essential to realize the full benefit of integrated testing strategies. Regulators and accreditation bodies are responding with updated guidance that emphasizes method validation, traceability, and standardized reporting, which in turn influences procurement cycles and vendor selection.

Assessing the operational consequences of 2025 tariff shifts on procurement, supply chain resilience, and service delivery in toxicology testing

Tariffs and trade policy introduced during 2025 have produced cumulative impacts that extend across procurement, instrument servicing, and consumables supply chains for toxicology laboratories. Increased duties on imported instrumentation and components can raise acquisition costs for chromatography systems, mass spectrometers, and PCR instruments, prompting laboratories to reassess purchasing timelines and prioritize modular upgrades over full platform replacements. Beyond capital equipment, tariffs on reagents, assay kits, and specialized consumables create variability in unit costs that influence test mix decisions and the economics of in-house versus outsourced confirmation services.

Suppliers who rely on globalized manufacturing networks face pressure to reconfigure supply chains, which may introduce lead time volatility and increased inventory holding as a hedge against further trade disruptions. Such dynamics encourage buyers to diversify vendor relationships and to negotiate long-term supply agreements that include contingency clauses for tariff-related price adjustments. For service-oriented offerings such as confirmation services and consultation services, tariffs exert an indirect influence by altering the cost base of laboratory operations and potentially shifting demand between domestic and international providers.

In response, laboratory managers and procurement teams should evaluate total cost of ownership more holistically, accounting for maintenance, calibration, and parts availability against initial purchase price. Strategic sourcing decisions will increasingly weigh the benefits of localized manufacturing and regional support networks that can mitigate tariff exposure, while also prioritizing vendors with transparent supply chain mapping and flexible contractual terms.

A layered segmentation perspective that connects test modalities, product portfolios, sample matrices, drug targets, applications, and end-user dynamics to actionable laboratory strategy

A granular view of segmentation clarifies where technological, clinical, and commercial priorities intersect across test types, product portfolios, sample matrices, drug targets, applications, and end users. Test types include chromatography and mass spectrometry platforms that are detailed into gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for high-confidence confirmatory testing, alongside immunoassay-based screening formats and molecular diagnostics that span next-generation sequencing and PCR-based testing; rapid testing options complete the spectrum and support decentralized screening points.

Product type segmentation ranges from chromatography systems and mass spectrometers to enzyme-linked immunosorbent assay kits, lateral flow immunoassay kits, PCR instruments, and a suite of services including screening services, confirmation services, and consultation services that guide method selection and result interpretation. Sample type considerations reflect differing pre-analytical workflows and detection windows, encompassing blood with plasma and whole blood distinctions, hair, oral fluid, saliva, and urine; each matrix presents unique extraction, stability, and interpretive challenges that inform test choice.

Drug class segmentation focuses on clinically and forensically relevant analytes such as amphetamines, benzodiazepines, cannabis, cocaine, and opiates. Application segments include clinical diagnostics, forensic testing, pain management, sports anti-doping, and workplace testing, each with distinct regulatory, turnaround time, and reporting requirements. End users span government and military laboratories, home care testing scenarios, hospitals and clinics, independent laboratories, and research institutes, creating a diverse demand profile where procurement cycles, required accreditation, and throughput expectations vary considerably. Together, these segmentation layers illuminate where investment in instrumentation, assay development, and service delivery will yield the greatest operational and clinical return.

Regional dynamics and regulatory diversity that influence technology adoption, supply chain strategy, and service delivery models across global toxicology testing markets

Regional dynamics shape technology adoption, regulatory compliance, and service delivery models in ways that are important for strategic planning and vendor engagement. In the Americas, healthcare systems and forensic networks tend to favor rapid adoption of high-resolution chromatography and mass spectrometry driven by centralized laboratory models, high-volume clinical testing, and established reimbursement pathways that support confirmatory testing. Regulatory expectations emphasize validated methodologies and chain-of-custody protocols that underpin forensic and workplace testing, while decentralized care trends are expanding demand for rapid and point-of-care screening options.

Europe, Middle East & Africa exhibit substantial heterogeneity in capability and regulatory frameworks. Established markets emphasize harmonized standards and accreditation, driving uptake of advanced analytical platforms and a growing interest in molecular diagnostics for complex cases. Emerging markets within the region focus on scalable screening solutions, training, and infrastructural investments to bridge gaps in laboratory capacity. Cross-border regulatory mechanisms and regional reference laboratories play a critical role in standardizing practice and enabling access to confirmatory services.

Asia-Pacific combines rapid technological adoption with large and diverse patient populations, creating high demand for both high-throughput laboratory platforms and cost-effective rapid tests. Investments in domestic manufacturing and regional supply chains are accelerating, supported by public health initiatives that integrate toxicology screening into clinical and forensic workflows. Across all regions, the interplay between local regulatory requirements, procurement practices, and supply chain resilience informs how laboratory leaders prioritize capital projects and vendor partnerships.

Competitive differentiation driven by integrated instrumentation, validated assay portfolios, service partnerships, and supply chain transparency in toxicology testing

Competitive positioning in toxicology drug screening reflects a mix of global instrument manufacturers, specialized assay developers, and service providers offering confirmation and consultation services. Key instrument vendors leverage integrated platforms that combine robust chromatography systems with high-sensitivity mass spectrometers, accompanied by software ecosystems for data acquisition, interpretation, and laboratory information management. These vendors differentiate on throughput capability, support networks, and method libraries that reduce validation timelines for complex panels.

Assay manufacturers and kit suppliers compete on sensitivity, specificity, lot-to-lot consistency, and ease of use, particularly for immunoassays and lateral flow tests that serve decentralized settings. PCR and sequencing instrument providers focus on automation, sample throughput, and bioinformatics support that enable molecular toxicology applications, while independent laboratories and service providers emphasize accreditation, chain-of-custody integrity, and rapid turnaround for confirmatory testing.

Partnerships between instrument manufacturers and service laboratories increasingly shape go-to-market approaches, allowing vendors to offer bundled solutions that combine hardware, consumables, and validation services. Companies that invest in training, remote diagnostics, and predictive maintenance for installed instrumentation gain competitive advantage by reducing downtime and total cost of ownership for end users. Finally, firms that transparently manage supply chains and demonstrate agility in tariff and trade environments position themselves as reliable partners for large-scale deployments and time-sensitive forensic contracts.

Practical strategic moves for leaders to bolster resilience, diversify testing pathways, and optimize procurement and workforce capabilities in toxicology services

Industry leaders should pursue a balanced approach that emphasizes resilience, agility, and clinical relevance. First, prioritize portfolio diversification across screening and confirmatory modalities so laboratories can match test selection to clinical and forensic needs while hedging against supply chain disruptions. Investing in both immunoassay-based rapid screens and chromatography-mass spectrometry confirmation capability ensures appropriate triage and maintains result integrity for high-stakes cases.

Second, strengthen supplier relationships with a focus on long-term contracts, local support capabilities, and clear escalation pathways for parts and servicing. Negotiating terms that address tariff volatility and lead-time contingencies reduces procurement risk and stabilizes operational budgets. Third, commit to workforce development by allocating resources to upskill analytical chemists and molecular technologists in mass spectrometric interpretation, molecular assay validation, and laboratory informatics. Cross-training enhances flexibility and supports hybrid testing models.

Fourth, adopt data governance and interoperability standards that facilitate result comparability across instruments, laboratories, and jurisdictions, including robust quality control programs and audit-ready documentation. Finally, incorporate scenario planning into capital investment decisions to account for regulatory shifts, reimbursement changes, and geopolitical trade dynamics, enabling faster pivots when external conditions change.

A rigorous multi-method research approach combining expert interviews, regulatory review, supply chain mapping, and technical performance evaluation to underpin practical insights

The research underpinning this analysis combined a multi-modal approach to ensure robustness and applicability across laboratory settings. Primary data collection included structured interviews with laboratory directors, procurement managers, and service providers to capture operational realities, procurement constraints, and validation practices. These qualitative insights were complemented by a systematic review of regulatory guidance, accreditation standards, and technical validation literature to ground discussions of method selection, reporting, and compliance.

Supply chain analysis examined vendor manufacturing footprints, logistics pathways, and tariff-sensitivity to assess procurement risk and lead-time volatility. Technical evaluation of instrumentation and assays was informed by performance specifications, peer-reviewed validation studies, and vendor method summaries to compare sensitivity, specificity, and throughput characteristics across platforms. The methodology also incorporated scenario-based analysis to explore the implications of trade policy changes and regional procurement variations on laboratory operations.

Triangulation across these sources ensured that conclusions reflect both field practice and documented performance, while expert review cycles validated interpretive frameworks and recommendations. Ethical considerations and data privacy protocols guided interview conduct and the handling of proprietary information throughout the research process.

A strategic synthesis emphasizing technology integration, supply chain resilience, and workforce development to ensure reliable and scalable toxicology services

In conclusion, toxicology drug screening is evolving into a more integrated, technology-driven field that requires strategic alignment across instrumentation, assay selection, supply chain management, and workforce capabilities. Laboratories and service providers that successfully navigate this evolution will be those that balance investment in high-confidence confirmatory platforms with pragmatic adoption of rapid and molecular screening tools to meet diverse clinical and forensic needs.

Operational resilience, enabled by diversified procurement strategies and supplier partnerships, will be critical in an environment shaped by tariff fluctuations and regional supply dynamics. Equally important is the development of internal expertise and interoperable data systems that allow organizations to extract maximal clinical value from test results while maintaining compliance with evolving regulatory expectations. By focusing on these areas-technology integration, supply chain agility, and human capital-decision-makers can translate analytical advancements into reliable, scalable services that meet the rising demand for timely and accurate toxicology testing.

This executive summary serves as a strategic roadmap for stakeholders aiming to align short-term operational decisions with longer-term capability development in toxicology screening.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Toxicology Drug Screening Market, by Test Type

  • 8.1. Chromatography And Mass Spectrometry
    • 8.1.1. Gas Chromatography-Mass Spectrometry
    • 8.1.2. Liquid Chromatography-Tandem Mass Spectrometry
  • 8.2. Immunoassay
  • 8.3. Molecular Diagnostics
    • 8.3.1. Next-Generation Sequencing
    • 8.3.2. PCR-Based Testing
  • 8.4. Rapid Testing

9. Toxicology Drug Screening Market, by Product Type

  • 9.1. Chromatography Systems
  • 9.2. Confirmation Services
  • 9.3. Consultation Services
  • 9.4. Enzyme-Linked Immunosorbent Assay Kits
  • 9.5. Lateral Flow Immunoassay Kits
  • 9.6. Mass Spectrometers
  • 9.7. PCR Instruments
  • 9.8. Screening Services

10. Toxicology Drug Screening Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Whole Blood
  • 10.2. Hair
  • 10.3. Oral Fluid
  • 10.4. Saliva
  • 10.5. Urine

11. Toxicology Drug Screening Market, by Drug Class

  • 11.1. Amphetamines
  • 11.2. Benzodiazepines
  • 11.3. Cannabis
  • 11.4. Cocaine
  • 11.5. Opiates

12. Toxicology Drug Screening Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Forensic Testing
  • 12.3. Pain Management
  • 12.4. Sports Anti-Doping
  • 12.5. Workplace Testing

13. Toxicology Drug Screening Market, by End User

  • 13.1. Government And Military Laboratories
  • 13.2. Home Care Testing
  • 13.3. Hospitals And Clinics
  • 13.4. Independent Laboratories
  • 13.5. Research Institutes

14. Toxicology Drug Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Toxicology Drug Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Toxicology Drug Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Toxicology Drug Screening Market

18. China Toxicology Drug Screening Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Alere Inc.
  • 19.8. ARK Diagnostics, Inc.
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories, Inc.
  • 19.11. Charles River Laboratories International, Inc.
  • 19.12. Danaher Corporation
  • 19.13. Eurofins Scientific SE
  • 19.14. F. Hoffmann-La Roche Ltd
  • 19.15. Laboratory Corporation of America Holdings
  • 19.16. Merck KGaA
  • 19.17. Mindray Bio-Medical Electronics Co., Ltd.
  • 19.18. OraSure Technologies, Inc.
  • 19.19. Ortho Clinical Diagnostics
  • 19.20. PerkinElmer, Inc.
  • 19.21. Quest Diagnostics Incorporated
  • 19.22. Shimadzu Corporation
  • 19.23. Siemens Healthineers AG
  • 19.24. Sysmex Corporation
  • 19.25. Thermo Fisher Scientific Inc.
  • 19.26. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY-MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RAPID TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONFIRMATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CONSULTATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CANNABIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY OPIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY FORENSIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SPORTS ANTI-DOPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GOVERNMENT AND MILITARY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOME CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 224. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 254. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. G7 TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 264. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. NATO TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL TOXICOLOGY DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY AND MASS SPECTROMETRY, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA TOXICOLOGY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)